Chest Computed Tomography (CT) Screening Study With Antibody Testing
Withdrawn
- Conditions
- Lung Cancer
- Registration Number
- NCT01203579
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to assess the value of EarlyCDT-Lung test and CT scan both in lung cancer detection and potential health economic outcomes.
- Detailed Description
EarlyCDT-Lung test and CT scan both for lung cancer detection and potential economic outcomes.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What autoantibody panels in EarlyCDT-Lung test correlate with lung cancer subtypes in NCT01203579?
How does EarlyCDT-Lung autoantibody screening compare to low-dose CT for lung cancer detection sensitivity?
Which molecular biomarkers predict response to EarlyCDT-Lung in high-risk populations per NCT01203579?
What adverse events are associated with CT screening in lung cancer detection for NCT01203579 participants?
How does EarlyCDT-Lung cost-effectiveness compare to competitor biomarker tests like Vizimag in lung cancer screening?
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Clinic in Rochester🇺🇸Rochester, Minnesota, United States